Why the study?
The association of estimated whole blood viscosity with hemodynamic parameters and prognosis in patients with heart failure with reduced ejection fraction had not been established.
Does estimated whole blood viscosity predict composite endpoints and mortality in patients with heart failure with reduced ejection fraction?
Does estimated whole blood viscosity predict composite endpoints and mortality in patients with heart failure with reduced ejection fraction?
Estimated whole blood viscosity is an independent predictor of composite endpoints and all-cause mortality in patients with HFrEF, with lower viscosity associated with worse outcomes.
Answers are grounded in this paper and cite their sources.
WBV may refine HFrEF risk stratification; leaves open whether viscosity modulation alters outcomes.
AIM: We aimed to investigate the association of estimated whole blood viscosity (WBV) with hemodynamic parameters and prognosis in patients with heart failure with reduced ejection fraction. MATERIALS & METHODS: Total of 542 patients were included and followed-up for median 13 months. RESULTS: The WBV parameters had negative relationship with right atrium pressure and positive correlation with cardiac index. The WBV parameters were found to be independent predictors of composite end point (CEP) and all-cause mortality. Every one cP increases of WBV(h) and WBV(l) were associated with 17 and 1% reductions of CEP. In Kaplan-Meier analysis, patients with low WBV quartiles were found to have significantly more CEP. CONCLUSION: Being an easily accessible and costless prognosticator, WBV seems to be a novel marker for determining prognosis and an emerging tool to individualize heart failure with reduced ejection fraction management.
No takes yet. Share an insight, caveat, or question.
Çetin et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: